Everest Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$340K Buy
1,298
+46
+4% +$11.8K 0.11% 71
2026
Q2
$315K Sell
1,252
-112
-8% -$24.1K 0.12% 68
2026
Q1
$297K Buy
1,364
+303
+29% +$67.2K 0.15% 55
2025
Q4
$242K Sell
1,061
-76
-7% -$17.3K 0.14% 57
2025
Q3
$263K Buy
1,137
+21
+2% +$4.28K 0.17% 56
2025
Q2
$207K Buy
1,116
+72
+7% +$13.4K 0.15% 65
2025
Q1
$219K Buy
+1,044
New +$203K 0.2% 48

Other funds holding ABBV

Everest Management's ABBV Position: Q3 2026 in Review

Everest Management increased its AbbVie (ABBV) stake by 3.7% in Q3 2026, buying an estimated $11.8K and bringing the position to 1,298 shares worth $340K. The position accounts for 0.11% of the portfolio, ranked #71.

Everest Management first reported a position in ABBV in Q1 2025 and has held it in 7 quarters since. 4,279 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Everest Management held 1,298 shares of AbbVie worth $340K as of Q3 2026.
  • Everest Management bought 46 AbbVie shares in Q3 2026, an estimated $11.8K.
  • AbbVie made up 0.11% of Everest Management's portfolio in Q3 2026, its #71 holding.
  • Everest Management first reported a position in AbbVie in Q1 2025 and has held it in 7 quarters since.
  • 4,279 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Everest Management's 13F filing for Q3 2026, filed 10 Nov 2026.